Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A user traveled to Turkey for a 5000-graft FUE hair transplant at ASMED Clinic with Dr. Koray Erdogan. They used finasteride before and after the surgery and shared detailed experiences, costs, and recovery tips.

The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.

A user had a hair transplant 16 years ago and lost hair after stopping finasteride. They're now using a combination of treatments including oral dutasteride, topical and oral minoxidil, Pyrilutamide, and microneedling, and have seen improved density but are unsure if it's enough to grow their hair out. They also had a bad experience with scalp micropigmentation (SMP) and are considering redoing it.

A user humorously discusses wanting to transplant all their hair into one dense circle on their scalp, leaving the rest of their head bald. Replies include a joke about performing the procedure and a story about someone using their hair to fight crime.

Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

DUPA and retrograde alopecia may not be solely DHT-based, and a biopsy is crucial for accurate diagnosis and treatment. Treatments mentioned include dutasteride, oral minoxidil, pioglitazone, clobetasol, calcipotriol, ketoconazole, and doxycycline, depending on the specific condition.

A 34 year old female with androgenic alopecia who has tried treatments such as Spironolactone, Desogen, Minoxidil and Finasteride in order to address her hair loss. It also details the experiences of other women taking Spironolactone for Female Pattern Hair Loss (FPHL).

A 27-year-old seeking affordable hair transplant clinics, particularly in Mexico, after using finasteride for years. Recommendations for Dr. Nader and Dr. Cortez were mentioned.

The user has been on a comprehensive hair loss treatment regimen for four years, including Dutasteride, topical and oral Minoxidil, and various other treatments, but has seen little progress and is considering a hair transplant. Despite trying multiple therapies, including PRP and exosome injections, the user is still experiencing hair thinning and is hesitant about trying peptides due to potential cancer risks.

A satirical discussion about a hair transplant, with humorous comments on graft placement and clinic choice. The conversation includes references to a "Rebuild a Scalp Clinic" and jokes about using pubic hair and overharvesting.

A 27-year-old male is using a regimen of topical finasteride, minoxidil, ketoconazole, and biotin for hair loss, and has recently started oral finasteride despite previous side effects. He is considering shaving his head and is advised that a hair transplant might be possible once hair loss stabilizes.

The user has been managing hair loss with microneedling, Nutrafol, topical finasteride/minoxidil foam, LLLT, and Nizoral, and plans to add oral minoxidil. They are seeing improvement and are cautious about using oral finasteride due to past gynecomastia concerns.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

A user shared their successful experience with hair regrowth and transitioning from male to female using minoxidil, finasteride, Nutrafol, microneedling, and hormone replacement therapy (HRT). They expressed gratitude for the results and encouraged others to explore treatments that align with their personal goals.

The conversation discusses the theory that scalp fibrosis contributes to male pattern baldness (MPB) by increasing DHT concentration, and mentions treatments like Minoxidil. The user seeks opinions on the theory and the effectiveness of scalp massages.

Mike, 46, is experiencing hair thinning at the temples and frontal hairline. He plans to try microneedling with a pen and topical dutasteride after oral minoxidil and finasteride showed limited effectiveness and oral dutasteride caused side effects.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

User experienced hair growth with finasteride and minoxidil, but after using tretinoin, faced aggressive thinning and hair loss. They plan to stop tretinoin for two months to see if the problem improves.

A user's 15-month experience with oral finasteride, minoxidil, zinc and vitamin C, caffeine, and microneedling as treatments for hair loss, which has yielded impressive results. Suggestions were made to stack a topical DHT blocker with the finasteride or increase the microneedling regimen, and it was suggested to re-evaluate at the two year mark.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

The user shared their three-year progress using finasteride and minoxidil for hair regrowth before undergoing a hair transplant procedure. They plan to continue the medication post-procedure due to its success and did not experience significant side effects.

The conversation humorously discusses diverting DHT from head to body hair and explores the idea of transplanting body hair to the scalp. It also mentions the potential for treatments to prevent DHT from affecting hair follicles.

A user underwent a hair transplant with 3500 grafts after trying treatments like finasteride and minoxidil, preferring a local clinic in Toronto over traveling to Turkey. The user plans to continue using finasteride to maintain existing hair, as the transplanted hair is DHT resistant.

The user experienced mental side effects from oral finasteride, such as brain fog and low mood, and switched to topical finasteride combined with minoxidil. They are monitoring mental clarity and hair progress after stopping oral finasteride.

A user is experiencing continued hair loss despite using 0.5mg dutasteride and 2.5mg minoxidil, and is seeking advice on why the treatments aren't working and how to address potential androgen receptor sensitivity. Replies suggest getting tested and considering scalp micropigmentation (SMP).

A user shared their positive experience 5 months after a hair transplant, emphasizing the importance of thorough research and using finasteride and minoxidil to control hair loss. They had 3700 grafts transplanted to the front/mid-scalp and used medications to fill in the crown.